Initial Experience with Cryoablation for Oligoprogressive Metastatic NSCLC on First-Line Immunotherapy

Authors:

Abstract
Background: This prospective study evaluated the initial outcomes of local cryoablation for patients with oligoprogressive metastatic non-small cell lung cancer (NSCLC) who were maintained on first-line immunotherapy. Methods: The study included patients diagnosed with oligoprogressive metastatic NSCLC while undergoing first-line immunotherapy. Clinical outcomes, treatment efficacy, and procedural complications of cryoablation were reviewed. Results: Ten patients with oligoprogressive metastatic NSCLC on first-line immunotherapy underwent percutaneous c Panwen ryoablation at West China Hospital between September 2024 and November 2025. All patients continued their original immunotherapy regimen following ablation. Technical success was defined as ≥90% coverage of the target lesion by the ablation zone. Postprocedurally, one patient experienced mild hemoptysis, and another developed a pneumothorax requiring drainage. No other significant adverse events occurred. The disease control rate at 3 months was 70% (7/10), and progression-free survival ranged from 1.7 to 6 months. Conclusions: In this initial case series, local cryoablation appears to be an effective and safe therapeutic strategy for managing oligoprogressive disease in metastatic NSCLC patients continuing first-line immunotherapy.